Abstract
This chapter presents the current state of knowledge of the pharmacotherapy of nocturia. An overview of the diagnostic evaluation is followed by discussion of the indications and efficacy of different classes of medications used to treat nocturia. Nocturia, defined as voiding that occurs during the hours of sleep, is common and bothersome. The underlying causes are multiple and diverse. Determining the underlying etiology is essential for choosing the appropriate therapy. Pharmacologic treatment should be guided by a thorough clinical evaluation and data derived from a frequency-volume chart. Possible medications include those for overactive bladder (OAB), those for benign prostatic hyperplasia, and those to reduce nocturnal urine production. A systematic approach is essential for the optimal treatment of nocturia. In the absence of nocturnal polyuria, medications for BPH or overactive bladder may be employed. NP is highly prevalent among patients with nocturia, however, and antidiuretic therapy should be considered when measures to address serious underlying etiologic conditions are ineffective.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):179–83.
Fitzgerald MP, Litman HJ, Link CL, McKinlay JB, Survey Investigators BACH. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol. 2007;177(4):1385–9.
Bosch JL, Weiss JP. The prevalence and causes of nocturia. J Urol. 2010;184(2):440–6. Review.
Tikkinen KA, Auvinen A, Johnson TM, Weiss JP, Keränen T, Tiitinen A, et al. A systematic evaluation of factors associated with nocturia—the population-based FINNO study. Am J Epidemiol. 2009;170(3):361–8.
Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J. 1983;287(6406):1665–7.
Hofmeester I, Kollen BJ, Steffens MG, Bosch JL, Drake MJ, Weiss JP, et al. Impact of the International Continence Society (ICS) report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. 2015;115(4):520–36.
Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Ruud Bosch JL. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol. 2000;164(4):1201–5.
Weiss JP. Prevalence of nocturnal polyuria in nocturia. J Urol. 2009;181((4):538.
Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991;229(2):131–4.
Yalkut D, Lee LY, Grider J, Jorgensen M, Jackson B, Ott C. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med. 1996;128(3):322–8.
Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
Andersson KE, Wein AJ. Pharmacologic management of lower urinary tract storage and emptying failure. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 1836–74.
Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243.
Dmochowski R, Wein AJ. Lower urinary tract pharmacotherapy for nocturia. In: Weiss JP, Blaivas JG, Van Kerrebroeck P, Wein AJ, editors. Nocturia: causes, consequences and clinical approaches. New York: Springer Science+Business Media; 2012. p. 127–34.
Brubaker L, Fitzgerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(7):737–41.
Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analysis. Eur Urol. 2012;62(6):1040–60.
Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J. 2010;21(7):847–54.
Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Ishizuka O, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol. 2011;86(1):170–4.
Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. J Urol. 2007;178(6):2488–94.
Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. BJU Int. 2010;105(1):58–66.
Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Frost HT, Massow U, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–12.
Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Siami P, Staskin DR. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62–8.
Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–6.
Zinner N, Gittelmen M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase II trial. J Urol. 2004;171(6 Pt 1):2311–5.
Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275–80.
Tikkinen KA, Johnson TM, Tammela TL, Sintonen H, Haukka J, Huhtala H, Auvinen A. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010;57(3):488–96.
Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992;6(3):832–9.
Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, Arai Y. Nocturia and benign prostatic hyperplasia. Urology. 2003;61(4):786–90.
Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl. 2005;4(2):61–8.
Speakman M. Efficacy and safety of tamsulosin OCAS. BJU Int. 2006;98(Suppl 2):13–7.
Bliwise DL, Holm-Larsen T, Goble S, Norgaard JP. Short time to first void is associated with lower whole-night sleep quality in nocturia patients. J Clin Sleep Med. 2015;11(1):53–5.
Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol. 2003;170(1):145–8.
Johnson TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178(5):2045–51.
Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92(3):257–61.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E, European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.
Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323(1):202–9.
Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.
Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274–9.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.
Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewaki P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.
Hammer M, Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide hormone analogue, desmopressin. J Pharmacol Exp Ther. 1985;234(3):754–60.
Vilhardt H. Basic pharmacology of desmopressin. Drug Invest. 1990;2(Suppl 5):2.
Sands JM. Molecular mechanisms of urea transport. J Membr Biol. 2003;191(3):149–63.
Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.
Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Bosch JLHR, Gacci M, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017;72(5):757–69.
Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441–7.
Van Kerrebroeck P. Nocturia and antidiuretic therapy. In: Weiss JP, Blaivas JG, Van Kerrebroeck P, Wein AJ, editors. Nocturia: causes, consequences and clinical approaches. New York: Springer Science+Business Media; 2012. p. 135–44.
Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int. 2002;89(9):855–62.
Lose G, Lalos O, Freeman RM, Van Kerrebroeck P, Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003;189(4):1106–13.
Van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study. Eur Urol. 2007;52(1):221–9.
Lose G, Mattiasson A, Walter S, Lalos O, Van Kerrebroeck P, Abrams P, Freeman R. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021–5.
Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, Abrams S, Cheng M, Wein A. Efficacy and safety of SER120 nasal spray in nocturia patients pooled analysis of 2 randomized, double-blind, placebo-controlled phase 3 trials. J Urol. 2018; https://doi.org/10.1016/j.juro.2018.04.050. Article in Press.
Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013;5(6):310–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bergman, A.M., Weiss, J.P. (2019). Pharmacotherapy for Nocturia. In: Cox, L., Rovner, E. (eds) Contemporary Pharmacotherapy of Overactive Bladder. Springer, Cham. https://doi.org/10.1007/978-3-319-97265-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-97265-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-97264-0
Online ISBN: 978-3-319-97265-7
eBook Packages: MedicineMedicine (R0)